✨ Health Notices
19 AUGUST
NEW ZEALAND GAZETTE
2471
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| 10ug Haemophilus influenzae type b oligosaccharide conjugated to 25 ug Diphtheria CRM₁₉₇ protein, and 12.5Lf Diphtheria toxoid (adsorbed), 5Lf tetanus toxoid (adsorbed) and 4IU (less than 16 OPU) of pertussis vaccine (adsorbed) in 0.5 ml | Solution for IM injection | Lederle Laboratories Division, American Cyanamid Company, Pearl River, New York, United States of America | Tetramune |
| Remoxipride hydrochloride 75 mg | Controlled release capsule | Astra Pharmaceutical Production AB, Sodertalje, Sweden | Roxiam CR |
| Remoxipride hydrochloride 100 mg/ml | Solution for injection | Astra Pharmaceutical Production AB, Sodertalje, Sweden | Roxiam |
| Doxycycline hyclate 100 mg | Tablet | Glaxo Manufacturing Services (NZ) Limited, Palmerston North | Doxycycline Hyclate |
| Lacidipine 2 mg, 4 mg | Tablets | Glaxo S.p.A., San Polo di Torrile, Parma, Italy | Lacipil |
| 10ug Haemophilus influenza type b polysaccharide conjugated to tetanus protein (Act-HIB) as a lyophilisate to be reconstituted with a suspension containing purified diphtheria toxoid (adsorbed) 30 IU minimum and purified tetanus toxoid (adsorbed) 30 IU minimum and bordetella pertussis inactivated suspension (adsorbed) minimum of 4 IU (less than 16 OPU) in 0.5 ml | Solution for IM or subcutaneous injection | Pasteur Merieux Serums et Vaccins, Marcy L’etoile, France | Act-HIB-DTP |
| Pefloxacin mesylate 400 mg/5 ml | Solution for IV infusion | Rhone-Poulenc Rorer Pharma Specialites, Monts, France | Peflacine Injection |
| Pefloxacin mesylate 400 mg | Tablet | Rhone-Poulenc Rorer Pharma Specialites, Monts, France | Peflacine |
Dated this 16th day of August 1993.
D. SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.
go7014
Mental Health (Compulsory Assessment and Treatment) Act 1992
Section 92 of the Mental Health (Compulsory Assessment and Treatment) Act 1992
Pursuant to section 92 of the Mental Health (Compulsory Assessment and Treatment) Act 1992, I, David Andrew Smyth, Acting Director-General of Health, hereby give notice as follows.
Notice
-
The notice referred to in the Schedule is hereby amended by replacing the words “Kenneth Douglas Whelan, manager of Whakatane” with the words “Robert William MacGregor, registered nurse of Whakatane” in the right hand column of the Schedule to the notice specified in the Schedule to this notice.
-
The notice referred to in the Schedule is hereby further amended by replacing the words “Homanya Khozouei, medical practitioner of Timaru” with the words “Homayoun Khozouei, medical practitioner of Timaru”.
Schedule
| Date of Notice | Reference |
|---|---|
| 6 July 1993 | New Zealand Gazette, 8 July, 1993, No. 103, pages 1959 and 1960 |
Dated at Wellington this 17th day of August 1993.
D. SMYTH, Acting Director-General.
go7031
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1993, No 124
NZLII —
NZ Gazette 1993, No 124
✨ LLM interpretation of page content
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social Welfare16 August 1993
Medicines, Distribution, Medicines Act 1981
- D. Smyth, Acting Director-General of Health
🏥 Amendment to Mental Health Notice
🏥 Health & Social Welfare17 August 1993
Mental Health, Notice Amendment, Compulsory Assessment
- Kenneth Douglas Whelan, Replaced by Robert William MacGregor
- Robert William MacGregor (Registered Nurse), Replaced Kenneth Douglas Whelan
- Homanya Khozouei (Medical Practitioner), Name corrected to Homayoun Khozouei
- Homayoun Khozouei (Medical Practitioner), Corrected name
- David Andrew Smyth, Acting Director-General of Health